FIG. 4.

Site-directed mutations explain the novel target site patterns. Details are as in the legend to Fig. 2. For each panel, the substrates were incubated with protein buffer (lane 1), the laboratory integrase (lane 2), a patient-derived integrase that makes the type 1 pattern (ED061-7, lane 3), the laboratory integrase with an S119T substitution (lane 4), a patient-derived integrase that makes the type 2 pattern (ED171-1, lane 5), the laboratory integrase with an S119G substitution (lane 6), or the laboratory integrase with a G106A substitution (lane 7). The amount of products formed in lanes 2 to 7 ranged from 25 to 52% in panel A, 8 to 27% in panel B, and 40 to 52% in panel C.